Second U.S. Patent from PTSD Programme

Solvonis Therapeutics plc

(“Solvonis” or the “Company”)

Granted Second U.S. Patent from PTSD Discovery Programme

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system (“CNS”) disorders, announces that it has been granted a second U.S. patent by the United States Patent and Trademark Office (“USPTO”) covering a further monoamine modulator compound series arising from its proprietary post-traumatic stress disorder (“PTSD”) discovery programme.

The patent, U.S. Patent No. 12,595,269, was issued on 7 April 2026 and covers a chemically distinct monoamine modulator series designed to modulate serotonin, dopamine and noradrenaline transporter systems (SERT, DAT and NET). The patent term is expected to run until 16 February 2043, subject to maintenance fee payments and any applicable extensions or adjustments.

PTSD is a large and underserved market affecting more than 20 million people across the UK, U.S. and major European markets, with limited approved pharmacological treatment options. Recent strategic activity in the sector, including Otsuka Pharmaceutical Co., Ltd.’s (“Otsuka”) agreement to acquire Transcend Therapeutics for total potential consideration of US$1.225 billion, reflects increasing focus by pharmaceutical companies on next-generation psychiatric treatments targeting core monoamine pathways.

This patent is a composition-of-matter patent, meaning it protects the compounds themselves rather than only specific uses or methods of manufacture. In pharmaceutical development, this form of protection is generally regarded as the most robust and commercially valuable, as it secures exclusive rights to the underlying molecules.

This second granted patent builds on a series of recent milestones across Solvonis’ PTSD discovery programme, including the USPTO Notice of Allowance announced in January 2026, the selection of SVN-114 as lead candidate in March 2026, and the grant of U.S. Patent No. 12,590,077 on 31 March 2026. Together, these milestones continue to strengthen and expand the Company’s protected chemistry estate in PTSD.

Importantly, the grant of two U.S. patents across two chemically distinct monoamine modulator series reinforces the breadth of the Company’s research platform and supports future optimisation, lifecycle management and follow-on development opportunities beyond a single lead asset.

Professor David Nutt, Chief Scientific Officer of Solvonis Therapeutics plc, commented: “This second patent reflects the breadth of our monoamine modulation research and the scientific strategy behind it. By exploring multiple chemically distinct series acting across SERT, DAT and NET, we increase the probability of identifying differentiated compounds with attractive translational and therapeutic profiles.”

Anthony Tennyson, CEO of Solvonis Therapeutics plc, added: “The grant of a second U.S. patent within a week further strengthens the long-term value of our PTSD programme and reinforces the depth of chemistry underpinning this discovery programme. In an area of clear unmet need and rising strategic and commercial interest, strong intellectual property matters. Securing patent protection across multiple novel chemical series strengthens our position as we advance SVN-114 and continue to expand our CNS pipeline.”

Enquiries:

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system (CNS) disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and discovery-stage compounds across addiction and psychiatry.

The Company’s lead programmes target Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with additional development and discovery work supporting expansion into further addiction and psychiatric indications, including stimulant use disorder and depressive disorders.

Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is preparing for a Phase 2b trial in the United States targeting moderate-to-severe AUD. The Company’s PTSD discovery programme has identified SVN-114 as a lead compound, emerging from a proprietary compound series designed to modulate key brain signalling systems associated with emotional processing and social behaviour.

In parallel, Solvonis is advancing proprietary CNS discovery programmes supported by a dedicated compound library to identify new small-molecule modulators of key neurotransmitter systems. This platform enables efficient early-stage innovation and supports the Company’s integrated approach to developing therapies across addiction and psychiatry.

With a capital-efficient development model and a focus on partnering opportunities, Solvonis aims to deliver sustained value through innovation in CNS therapeutics.

solvonis.com | LinkedIn | X (Twitter)